Blog Archive

Αλέξανδρος Γ. Σφακιανάκης

Tuesday, October 26, 2021

Filamin-A expression in laryngeal squamous cell carcinoma and its clinical significance

xlomafota13 shared this article with you from Inoreader

Histol Histopathol. 2021 Oct 22:18383. doi: 10.14670/HH-18-383. Online ahead of print.

ABSTRACT

BACKGROUND: Laryngeal squamous cell carcinomas (LSCCs) are tumours with a high incidence of treatment failure and recurrence. Recent strategies to improve the five-year survival rate and to decrease the rates of recurrence and metastases did not improve outcomes significantly. Research efforts in recent years have started focusing on discovering biomarkers of prognosis and management in LSCCs. Filamin-A reportedly has been associated with metastatic disease in a recent study. Analysis of this protein's expression in LSCCs is lacking in the literature.

MATERIALS AND METHODS: This study analysed the expression of filamin-A, using immunohistochemistry, in a tissue microarray of 80 cases of laryngeal squamous cell cancers. Clinical-pathological parameters were analysed according to filamin-A expression in the tissue microarray. Furthermore , a review of possible mechanisms of this protein in cancer, in general, was presented, along with a review of the protein's expression in other head and neck tumours.

RESULTS: A significant majority of laryngeal squamous cell cancers exhibited positive expression of filamin-A protein. All the filamin-A positive tumours expressed it in their cytoplasm. Significant correlation between filamin-A expression and grade, stage, lymph node status and metastases were found.

CONCLUSION: The above may suggest an important role for filamin-A in LSCCs. Overall, filamin-A expression in laryngeal cancer is in line with evidence seen in other head and neck cancers. Further studies are in order to pinpoint the exact role of this protein in LSCCs, and its possible utilization in the management of these difficult-to-treat tumours.

PMID:34677823 | DOI:10.14670/HH-18-383

View on the web

No comments:

Post a Comment